Clinical Trial

A Study of GC101 TIL in Advanced Breast Cancer (10hospital)

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy (GC 101 TIL) in patients with advanced breast cancer. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-11-24; most recent amendment 2025-12-04.
Trial Details
NCT Number NCT05142475
Lead Sponsor Shanghai Juncell Therapeutics
Collaborators: Shanghai 10th People's Hospital
Conditions Breast Cancer, Treatment Side Effects, Advanced Breast Cancer, Effects of Immunotherapy
Enrollment 50 participants
Start Date 2021-11-19
Primary Completion 2026-12-20 (estimated)
Study Completion 2027-12-20 (estimated)
Updated on ClinicalTrials.gov 2025-12-11